NYSE:LLYPharmaceuticals
Eli Lilly Defends GLP‑1 Franchise As EBGLYSS Data Support Diversification
Eli Lilly (NYSE:LLY) secured a partial legal win in its case against Fella Health over alleged misleading marketing of compounded tirzepatide.
The court allowed core claims around consumer confusion and false advertising to continue, while rejecting other elements of Lilly’s complaint.
Separately, four year data from the ADlong Phase 3b extension study showed durable skin clearance and itch relief with EBGLYSS (lebrikizumab-lbkz) in atopic dermatitis.
Both updates affect Lilly’s positioning...